Goldman Sachs Group INC Schedule 13G passive stakes

Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC have filed an amended Schedule 13G, reporting beneficial ownership of 1.6% of Acadia Healthcare Company, Inc.'s common stock as of March 31, 2026.

The Goldman Sachs Group, Inc. has filed a Schedule 13G disclosing beneficial ownership of 7.3% of XFLH Capital Corporation's ordinary shares.

The Goldman Sachs Group, Inc. has filed a Schedule 13G reporting a 4.5% beneficial ownership stake in PBF Energy Inc. as of March 31, 2026.

The Goldman Sachs Group, Inc. has filed a Schedule 13G reporting a 5.3% beneficial ownership stake in Lake Superior Acquisition Co.

The Goldman Sachs Group, Inc. has filed a Schedule 13G reporting a 0.5% beneficial ownership stake in Jasper Therapeutics, Inc.

The Goldman Sachs Group, Inc. has filed a Schedule 13G reporting a 5.1% beneficial ownership stake in Harvard Ave Acquisition Corp.

The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC have filed a Schedule 13G reporting beneficial ownership of 3.2% of GigCapital7 Corp. Class A ordinary shares.

The Goldman Sachs Group, Inc. has filed a Schedule 13G reporting beneficial ownership of 4.6% of Brand Engagement Network Inc. common stock.

The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC have filed a Schedule 13G regarding their beneficial ownership of Crane Harbor Acquisition Corp.

The Goldman Sachs Group, Inc. has filed a Schedule 13G reporting beneficial ownership of 23.3% of QVC Group Inc's 8.0% Series A Cumulative Redeemable Preferred Stock.

Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have reported beneficial ownership of 8.1% of Coreweave, Inc.'s Class A common stock as of March 31, 2026.

Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have filed a Schedule 13G, disclosing a beneficial ownership stake of 6.4% in Chart Industries, Inc.

Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have filed an amended Schedule 13G, reporting beneficial ownership of 1.3% of Cartesian Growth Corp III's Class A Ordinary Shares as of March 31, 2026.

Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have filed an amended Schedule 13G, reporting beneficial ownership of 0.9% of Cantor Equity Partners II Inc.'s Class A ordinary shares.

The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC have filed an amended Schedule 13G, reporting beneficial ownership of 4.8% of Andretti Acquisition Corp II's Class A Ordinary Shares.

Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have filed a Schedule 13G, reporting beneficial ownership of 7.8% of Allied Gold Corporation's common stock as of March 31, 2026.

Vanguard Capital Management has reported beneficial ownership of 21,224,791 shares, representing 7.19% of the outstanding common stock of Goldman Sachs Group Inc.

The Goldman Sachs Group, Inc. has filed a Schedule 13G reporting a 5.1% beneficial ownership stake in PagerDuty, Inc.

The Vanguard Group has reported a 0% beneficial ownership in Goldman Sachs Group Inc. following an internal realignment that shifted reporting responsibilities to its subsidiaries.

Goldman Sachs Group and its subsidiary Goldman Sachs & Co. LLC reported a 6.0% beneficial ownership in M3-BRIGADE ACQUISITION VI CORP's Class A Ordinary Shares.

The Goldman Sachs Group and its subsidiary have reported a 2.7% beneficial ownership stake in Intellia Therapeutics, Inc. as of December 31, 2025.

The Goldman Sachs Group, Inc. and its subsidiary, Goldman Sachs & Co. LLC, reported a 12.8% beneficial ownership stake in Inflection Point Acquisition Corp. IV.

Goldman Sachs Group and its affiliate have reported a 7.7% beneficial ownership stake in Xerox Holdings Corp, held in the ordinary course of business.

Goldman Sachs Group and its affiliate have reported a 4.2% beneficial ownership stake in Kohl's Corporation common stock.

Goldman Sachs Group and its subsidiary Goldman Sachs & Co. LLC have reported a 6.3% beneficial ownership stake in Jasper Therapeutics Inc. common stock.

Goldman Sachs Group and its subsidiary, Goldman Sachs & Co. LLC, reported a 2.9% beneficial ownership stake in Indivior Pharmaceuticals, Inc. as of December 31, 2025.

Goldman Sachs Group and its subsidiary have reported a 4.8% beneficial ownership stake in Delek US Holdings, Inc. as of December 31, 2025.

The Goldman Sachs Group and its affiliate have reported a 5.5% beneficial ownership stake in human capital management software provider Dayforce, Inc.

Goldman Sachs Group and its subsidiary Goldman Sachs & Co. LLC have reported a 5.3% beneficial ownership stake in Crane Harbor Acquisition Corp.'s Class A ordinary shares.

The Goldman Sachs Group, Inc. and its subsidiary, Goldman Sachs & Co. LLC, have reported a 5.9% beneficial ownership stake in Cantor Equity Partners II Inc.'s Class A ordinary shares.